News

A Slight Chemical Alteration Makes a TB Drug More Effective

Tuberculosis continues to become more resistant to existing drug regimens resulting in a need for constant innovation on the part of drug researchers. In an article published by Medicalxpress.com which can be found here, researchers are reported to have found a chemical alteration that makes fluoroquinolones, an existing group of TB-fighting drugs, more effective against drug resistant TB. The article provides an in-depth characterization of the TB enzymes targeted by fluoroquinolones and the mutations that cause resistance. The researchers discovered that by creating a critical change in the chemical composition of moxifloxacin, a broad-spectrum fluoroquinolone antibacterial, they were able to overcome the resistance caused by these mutated enzymes. This could mean more effective treatment for TB patients.

More News
23 Aug 2022
The PAN-TB collaboration announced initial plans for a Phase 2 clinical trial evaluating two novel drug regimens to treat Tuberculosis. Sponsored by the Bill and Melinda Gates Foundation, the PAN-TB, or “Project to Accelerate New Treatments for Tuberculosis”, collaboration brings together non-...
4 May 2022
Earlier this week, the World Health Organization (WHO) released a rapid communication which detailed the upcoming changes to the treatment guidance for drug-resistant tuberculosis (DR-TB). These guidelines are used to inform national TB programmes globally on how to treat patients with these...
5 Apr 2022
On April 01, 2022, the Stop TB Partnership launched the second online consultation for the new Global Plan to End TB 2023-2030. Over the years, the Global Plans have been important tools for advocacy and resource mobilization, and served as a reference document for donors and stakeholders. In May...